What is the appropriate management for a nil‑by‑mouth patient with a blood glucose of 14 mmol/L and a ketone level of 1.4 mmol/L?

Management of NBM Patient with Blood Glucose 14 mmol/L and Ketones 1.4 mmol/L

This patient requires immediate insulin therapy—either subcutaneous or intravenous—because a ketone level of 1.4 mmol/L meets the diagnostic threshold for diabetic ketoacidosis (DKA), regardless of the relatively modest hyperglycemia. 1

Immediate Assessment

• Check serum potassium immediately before any insulin is given; if K⁺ < 3.3 mEq/L, insulin must be withheld and potassium aggressively repleted first to prevent fatal cardiac arrhythmias (Class A evidence). 2
• Obtain venous blood gas, serum bicarbonate, anion gap, and β-hydroxybutyrate to confirm DKA and assess severity; a ketone level of 1.4 mmol/L is at the diagnostic cut-off for acetoacetate in DKA. 1
• Measure corrected serum sodium by adding 1.6 mEq/L for each 100 mg/dL (5.6 mmol/L) glucose above 100 mg/dL (5.6 mmol/L). 2
• Perform ECG if potassium is abnormal or if the patient has cardiac risk factors. 2

Fluid Resuscitation Protocol

• Begin isotonic saline (0.9% NaCl) at 15–20 mL/kg in the first hour (approximately 1–1.5 L in an average adult) to restore intravascular volume. 2
• After the first hour, if corrected sodium is normal or elevated, switch to 0.45% NaCl at 4–14 mL/kg/hr; if corrected sodium is low, continue 0.9% NaCl at the same rate. 2
• Add 20–30 mEq/L potassium to IV fluids (2/3 potassium chloride and 1/3 potassium phosphate) once serum K⁺ is 3.3–5.5 mEq/L and urine output is adequate. 2

Insulin Therapy Decision Algorithm

If Serum Bicarbonate ≥18 mEq/L and pH >7.3 (Mild or No DKA)

• Start subcutaneous rapid-acting insulin (lispro, aspart, or glulisine) at 0.1–0.2 U/kg every 1–2 hours combined with aggressive IV fluid replacement; this approach is as effective as IV insulin for hemodynamically stable patients with mild-moderate DKA and is more cost-effective. 2
• Continue subcutaneous insulin until ketones fall below 1.0 mmol/L, even if glucose normalizes. 2

If Serum Bicarbonate <18 mEq/L or pH <7.3 (Moderate-Severe DKA)

• Initiate continuous IV regular insulin infusion at 0.1 U/kg/hr after confirming K⁺ ≥3.3 mEq/L; this is the preferred method for moderate-to-severe DKA. 2
• An initial IV bolus of 0.1 U/kg regular insulin may be given in adults, but should be omitted in children to reduce cerebral edema risk. 2
• Target a glucose decline of 50–75 mg/dL per hour; if the decline is <50 mg/dL in the first hour, verify hydration and double the insulin infusion rate hourly until the target is achieved. 2

Glucose Management During Insulin Infusion

• When plasma glucose falls to 250 mg/dL (13.9 mmol/L), switch IV fluids to 5% dextrose with 0.45–0.75% NaCl while maintaining the same insulin infusion rate to allow continued ketone clearance. 2
• In euglycemic DKA (initial glucose <250 mg/dL), start dextrose-containing fluids immediately with insulin to prevent hypoglycemia while clearing ketones. 2
• Provide 150–200 g of carbohydrate per day (via IV dextrose or oral intake if tolerated) to suppress ongoing ketogenesis. 2

Monitoring Protocol

• Check blood glucose every 1–2 hours during active insulin therapy. 2
• Measure serum potassium, electrolytes, venous pH, bicarbonate, and anion gap every 2–4 hours until metabolically stable. 2
• Monitor β-hydroxybutyrate directly rather than relying on urine ketones, which lag behind serum clearance and may mislead clinicians. 2

Resolution Criteria and Transition to Subcutaneous Insulin

• DKA is resolved only when all of the following are met simultaneously: glucose <200 mg/dL, bicarbonate ≥18 mEq/L, pH >7.3, anion gap ≤12 mEq/L, and β-hydroxybutyrate <1.0 mmol/L. 2
• Administer long-acting basal insulin (glargine or detemir) 2–4 hours before stopping IV insulin to prevent rebound hyperglycemia and recurrent DKA; this overlap is mandatory. 2
• Continue IV insulin for an additional 1–2 hours after the basal dose to ensure adequate absorption. 2
• Use approximately 50% of the total 24-hour IV insulin dose as the single daily basal dose, and divide the remaining 50% equally among three meals as rapid-acting prandial insulin. 2

Resumption of Oral Intake

• Oral intake may be started when the patient is clinically stable—alert, without Kussmaul respirations, and showing no signs of ongoing metabolic decompensation—even if formal DKA resolution criteria are not yet met. 3
• Clinical stability alone permits feeding; biochemical resolution (pH >7.3, bicarbonate ≥18 mEq/L) is not required before initiating oral intake in a stable patient. 3
• Administer anti-emetic medication promptly to facilitate early resumption of oral carbohydrate intake. 2
• Aim for 45–50 g of carbohydrate every 3–4 hours, delivered as liquid or soft foods if solid meals are not yet tolerated. 2

Critical Pitfalls to Avoid

• Never start insulin if serum potassium is <3.3 mEq/L; this can precipitate fatal cardiac arrhythmias and is an absolute contraindication. 2
• Never stop IV insulin without a 2–4 hour overlap of subcutaneous basal insulin; abrupt cessation is the most common cause of recurrent DKA. 2
• Never withhold insulin when glucose normalizes during DKA; continuous insulin is required for ketone clearance regardless of glucose levels. 2
• Do not rely solely on urine ketone strips; they lag behind serum β-hydroxybutyrate clearance and may mislead during treatment. 2

Special Considerations for Youth with Type 2 Diabetes

• In youth presenting with ketosis/ketoacidosis, treatment with subcutaneous or intravenous insulin should be initiated to rapidly correct hyperglycemia and metabolic derangement; once acidosis is resolved, metformin should be initiated while subcutaneous insulin therapy is continued. 4